FEB 25, 2019 03:40 PM PST

Open-Science Model Advances Drug Discovery

WRITTEN BY: Nouran Amin

Parkinson’s disease and Amyotrophic Lateral Sclerosis is the latest push for Medicines 4 Neurodegenerative Diseases (M4ND Pharma) by academic scientists in Toronto in their promising pursuit for a new genetic drug that targets intractable nervous system disorders. Thanks to funding from the Krembil Foundation, M4ND Pharma will be the world's second drug discovery company dedicated to open science after Medicines 4 Kids (M4K Pharma). Similar to M4K Pharma, M4D will not seek patents on its findings but will instead rely on regulations regarding data exclusivity for the reasons of supporting the open science movement.

In open science, researchers can share resources and exchange knowledge without limitations due to patents and the peer review publishing process. The aim of open science is to advance scientific discovery—it was the same movement that garnered the Human Genome Project, and the non-profit Structural Genomics Consortium (SGC).

"When we started M4K, many people thought an open approach to late-stage drug development might only be applicable to rare or neglected diseases, if at all," says Aled Edwards, a professor of molecular genetics at the University of Toronto and CEO of the SGC. "But we're getting unexpected funding and scientific contributions from industry, academic and clinical sources, and slowly but surely we're advancing a medicine through the pipeline. It's time to move the goal posts again on what's possible with open science."

Learn more about open science:

fordable medicines faster, but it's been incredibly challenging to make it happen because the system is complicated," says Edwards. "The key was to invent a different business model, and we're extraordinarily happy that industry, academia and others have been delighted to contribute."

Source: University of Toronto

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 21, 2019
Health & Medicine
OCT 21, 2019
Ketamine is not an opioid, and treats depression in a novel way
In March, the U.S. Food and Drug Administration approved ketamine nasal spray to treat depression. Ketamine has gotten a bad rep as an opioid - which it is...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
What does MDMA Therapy Look Like?
The Multidisciplinary Association for Psychedelic Studies (MAPS) aims to create an FDA-approved standardized MDMA-assisted psychotherapy practice for PTSD ...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
MDMA Treats Social Anxiety in Autistic Adults
People with autism are more likely than those without to develop social anxiety (Bejerot: 2014). Meanwhile, current anti-anxiety medications and therapeuti...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
The Three Drugs that Reverse Biological Aging
In the last 100 years, life expectancy in the US has risen from 55 years until 79 (Roser: 2019). And with the continuous development of medicine and scie...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Peptide-Based Therapeutics Advances Alzheimer Disease Research
Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasc...
Loading Comments...